Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), significantly reduces the risk of death and major heart and kidney events compared with spironolactone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
This article was originally published on MedicalXpress.com
By Daniel Zane Bryant, author of “Living with Food Allergies: A Complete Lifestyle Guide” (available on Amazon at https://www.amazon.com/dp/B0G2BcGB2K) Navigating food allergies might initially feel overwhelming, yet it presents an exciting opportunity to reimagine familiar […]
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
© 2025 SimplyWell.ca